We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Genetic "Hotspots” Tailor Therapies for Bowel Cancer Treatment

By LabMedica International staff writers
Posted on 22 Feb 2010
A new study has identified the repetition frequency of new genetic "hotspots,” which could help doctors offer personalized therapies for bowel cancer patients.

Researchers at the University of Dundee (United Kingdom) carried out a genetic analysis on 106 bowel cancer tumor samples to search for the frequency of known faults in a key gene called K-Ras--an important protein which acts as an "on-off switch” in cells to control growth--since it is already known that in some bowel cancers the K-Ras gene is faulty, leaving the switch permanently "on.” The researchers screened the colorectal tumors for additional K-Ras mutation phenotypes and Ras guanine triphosphate (GTP)-ase activating assays and gene and pathway changes induced by individual K-Ras mutants. More...


The researchers found that besides the current K-Ras "hotspots” in codons 12, 13, and 61, four additional K-Ras mutations (Leu19Phe, Lys117Asn, Ala146Thr, and Arg164Gln) were identified, most commonly at codon 146. The researchers additionally identified a new K-Ras gene amplification event, present in approximately 2% of tumors. According to the researchers, the study suggests that as many as 33% of bowel cancer patients have a K-Ras fault. As a result, they recommend future mutation screening to facilitate optimal patient selection for treatment with Epidermal Growth Factor Receptor (EGFR)-targeted therapies should therefore be extended to codon 146, and in addition should consider the unique molecular signatures associated with individual K-Ras mutations. The study was published early online on February 9, 2010, in the British Journal of Cancer.

"These results highlight additional gene faults which potentially could be tested for in bowel cancer patients to determine which people will respond best to which drugs,” said lead author Gillian Smith, Ph.D. "The next stage is to develop effective tests to screen for these mutation 'hotspots' to help doctors to plan the most effective treatment strategies for bowel cancer patients - and this will encourage scientists to also focus their efforts on finding new treatments for patients with faulty K-Ras genes to give them more options.”

Targeted therapies are drugs that are designed to treat cancer cells while minimizing damage to normal, healthy cells. The drugs interfere with specific pathways involved in cancer cell growth or survival, such as blocking growth signals and reducing the blood supply to cancer cells; others stimulate the immune system to recognize and attack the cancer cell. The two types of targeted therapy that are currently being used for colorectal cancer are EGFR inhibitors--such as panitumumab, a monoclonal antibody that binds to and blocks EGFR--and antiangiogenic drugs.

Related Links:

University of Dundee



New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automated Urinalysis Solution
UN-9000
New
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The method that profiles DNA methylation in cell-free DNA from a single blood sample to detect disease signals system-wide (photo courtesy of Shutterstock)

cfDNA Methylation Assay Enables Multi-Disease Detection from Single Blood Sample

Early, accurate detection of cancer and organ disease remains limited by cost, reliance on targeted mutation assays, and uncertainty about the signal’s tissue of origin. Many liquid biopsy approaches require... Read more

Immunology

view channel
Image: Mycobacterium tuberculosis bacteria seen with a scanning electron microscope (Credit: CDC PHIL)

Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection

Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.